United States Ex Rel. Bogart v. King Pharmaceuticals

493 F.3d 323, 2007 U.S. App. LEXIS 16849, 2007 WL 2028124
CourtCourt of Appeals for the Third Circuit
DecidedJuly 16, 2007
Docket06-2098
StatusPublished
Cited by9 cases

This text of 493 F.3d 323 (United States Ex Rel. Bogart v. King Pharmaceuticals) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States Ex Rel. Bogart v. King Pharmaceuticals, 493 F.3d 323, 2007 U.S. App. LEXIS 16849, 2007 WL 2028124 (3d Cir. 2007).

Opinion

OPINION

VANASKIE, District Judge.

Appellant/Relator Edward Bogart (“Bogart”) commenced this qui tam litigation on behalf of the United States, the District of Columbia, and ten states with qui tam legislation. 1 Appellees King Pharmaceuticals and Monarch Pharmaceuticals (collectively, “King”) ultimately settled the claims of the jurisdictions with qui tam statutes, and Bogart was paid counsel fees and expenses of approximately $800,000, plus relator fees in excess of $9 million. King also entered into settlement agreements with the nearly 40 States without qui tam legislation who were not parties to this case. Contending that his efforts produced settlements totaling more than $30 million for the non-gm tam States, Bogart unsuccessfully argued in the District Court that he was entitled to be paid up to one-third of that amount as attorneys’ fees under a common fund theory of recovery. He has appealed the District Court’s ruling. Finding no merit in Bogart’s contentions, we will affirm the District Court.

I

On March 12, 2003, Bogart commenced a qui tam action against King under the False Claims Act (“FCA”), 31 U.S.C. §§ 3729-3732. 2 He also asserted claims on behalf of ten states and the District of Columbia that had statutes similar to the FCA, seeking a relator’s share and attorneys’ fees under these statutes as well. 3 *326 Bogart, a former employee of King, alleged that King misrepresented pricing information it supplied to the federal and state governments as a condition of its participation in various Medicaid programs.

Bogart filed amended complaints on July 1, 2003, and June 17, 2004, to assert claims on behalf of Appellee Virginia and New Mexico, respectively, which had recently enacted false claims statutes. In accordance with the FCA, the original complaint and the amended complaints were filed under seal.

At the time Bogart filed the second amended complaint, the United States permitted notification to the qui tam States of this litigation. Bogart was also permitted to notify the National Association of Medicaid Fraud Control Units (“NAMFCU”), an association of state attorney general offices that coordinates interstate efforts to prosecute Medicaid fraud claims

After notice of this lawsuit, the NAM-FCU formed a committee to negotiate a settlement with King on behalf of its members, many of whom did not have qui tam statutes and were not parties to this litigation. Each state individually negotiated with King as well. Bogart did not participate in these settlement discussions.

On September 22, 2004, in anticipation of impending settlements, Bogart filed a Third Amended Complaint, asserting a request for “Common Fund Relief’ with respect to amounts recovered by non-qui tam jurisdictions. In Paragraph 221 of the Third Amended Complaint, Bogart asserted:

While the states possessing qui tam statutes have a regulatory scheme for rewarding the Relator for coming forward, those which have none will potentially receive a windfall with little or no investigation or commitment of time or resources .to the recovery. The Common Fund doctrine preserves the right of the litigant or counsel to an award from the Common Fund generated.

Bogart sought recovery of up to one-third of the purported common fund, although he did not specify whether this percentage represented a relator’s share or counsel fees.

On October 31, 2005, the United States, the States, and King announced an aggregate settlement of $124,057,318. Of this amount, $73,420,225 was payable to the United States; $20,239,317 was payable to the qui tam States; and $30,397,776 was payable to the non-qui tam States. Bogart did not participate in the negotiation of the settlements and was not a party to any of the settlement agreements.

King executed separate settlement agreements with the United States and each individual state. Although the Federal Settlement Agreement noted that King agreed to pay the States $50,637,093, the agreement explicitly stated that King’s obligation to pay the United States was independent of King’s settlement agreements with the individual States, and that “King’s obligation to pay the State Settlement Amount ... shall arise only under the NAMFCU Agreement and the State Settlement Agreements.”

On October 30, 2005, one day before the announcement of the settlements, Bogart moved for emergency injunctive relief to restrain King from making any payments pursuant to the settlement agreements. Among other things, Bogart alleged that he would be irreparably harmed if King paid the non-gm tam settlements — the so-called “common fund” — because the District Court would no longer have jurisdiction to provide from the settlement amounts what Bogart contends are his legal entitlements.

On October 31, 2005, the District Court denied Bogart’s motion for a temporary restraining order. The court deferred *327 consideration of Bogart’s preliminary injunction motion until after the completion of pertinent discovery.

On December 20, 2005, Bogart filed his First Amended Petition for Fees, claiming that he was entitled to one-third of the aggregate settlement proceeds payable to the non-qui tam States under the common fund doctrine. Though one might conclude that, given its title, the petition was for counsel fees, Bogart once again failed to specify within the submission whether this percentage constituted a relator’s share or counsel fees. The Amended Petition, however, stated that King had agreed to pay all fees and expenses to which Bogart was entitled under the FCA fee-shifting provision, 31 U.S.C. § 3730(d)(1). 4

The District Court addressed Bogart’s claim for relief under the common fund doctrine in connection with its decision on a motion to dismiss filed by New Mexico, one of the two States Bogart added to this case in amended complaints. United States ex rel. Bogart v. King Pharms., 410 F.Supp.2d 404 (E.D.Pa.2006). New Mexico argued that its false claims statute did not apply because King’s alleged fraudulent activity had ended before New Mexico’s false claims statute went into effect on May 19, 2004. The District Court agreed that the statute could not apply retroactively and dismissed the claim under the New Mexico False Claims Act. 5 Id. at 408.

Bogart argued alternatively that he was entitled to a share of New Mexico’s settlement under the common fund doctrine. In a well-reasoned opinion, the District Court concluded that the common fund theory of recovery did not apply. Id. at 409-10.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Andrews v. City of New York
118 F. Supp. 3d 630 (S.D. New York, 2015)
Virginia ex rel. Hunter Labs LLC v. Quest Diagnostics Inc.
100 F. Supp. 3d 542 (E.D. Virginia, 2015)
Robert Lampl v. Diana Miller
Third Circuit, 2012
In re Howard
465 F. App'x 152 (Third Circuit, 2012)
Humphrey v. United Way of the Texas Gulf Coast
802 F. Supp. 2d 847 (S.D. Texas, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
493 F.3d 323, 2007 U.S. App. LEXIS 16849, 2007 WL 2028124, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-bogart-v-king-pharmaceuticals-ca3-2007.